Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 2.02, 7.01, 8.01, 9.01 · 8-K

Insight Molecular Diagnostics Inc.

IMDXNASDAQEQUITYCurrent

Results of Operations and Financial Condition · Regulation FD Disclosure · Other Events

Item 2.02 Results of Operations and Financial Condition. On August 10, 2026, Insight Molecular Diagnostics Inc. (“we,” “us,” “our,” the “Company” or “iMDx”) issued a press release announcing our financial results for the three and six months ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1, which, in its entirety, is incorporated herein by reference.…

Filed Aug 10, 2026Accepted Aug 10, 2026, 4:10 PM EDTCIK 1642380Accession 0001493152-26-036863
Share

Company context

Current securities

Recent company filings

  1. 4 filingNov 20, 2026
  2. 4 filingNov 19, 2026
  3. Entry into a Material Definitive Agreement · Other EventsNov 18, 2026
  4. 424B5 filingNov 18, 2026
  5. 424B5 filingNov 16, 2026

Registered securities in this filing

Insight Molecular Diagnostics Inc. · 8-K · Filed 2026-08-10

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common stock, no par value

Symbol
IMDX
Exchange
NASDAQ
Classification
COMMON
Status
Current
Filing context

Context: AsOf2026-08-10

Dimensions: Not supplied

Accession 000149315226036863 · 1 registered-security cover member

Read the exact SEC filing ↗

Disclosure sections

Items 2.02, 7.01, 8.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 2.02Item 2.02 - Results of Operations
Item 2.02 Results of Operations and Financial Condition. On August 10, 2026, Insight Molecular Diagnostics Inc. (“we,” “us,” “our,” the “Company” or “iMDx”) issued a press release announcing our financial results for the three and six months ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1, which, in its entirety, is incorporated herein by reference. The information in this Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. Such information shall not be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as otherwise expressly set forth by specific reference in such filing.
Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On August 10, 2026, the Company announced that it had received an Additional Information Request (“AIR”) from the FDA regarding its submission for GraftAssureDx, to which the Company must provide a complete response within 180 days. The Company believes the AIR is a routine part of the FDA submission process and is prepared to provide its complete response to the AIR. The Company expects to have one more meeting with the FDA before the fourth quarter of this year. The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. Such information shall not be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as otherwise expressly set forth by specific reference in such filing.
Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events. The information provided in “Item 7.01 - Regulation FD Disclosure” of this Current Report on Form 8-K is incorporated by reference into this Item 8.01. Cautionary Note Regarding Forward-Looking Statements Certain statements in this Current Report on Form 8-K may be considered “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements other than statements of historical fact contained in this Current Report. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon assumptions that, while considered reasonable by the Company and its management, are inherently uncertain. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made or to reflect the occurrence of unanticipated events.
Filed exhibits (1)
EX-99.1 (by filename) ex99-1.htm

EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 IMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDx Discussions with FDA advance toward expected marketing authorization for GraftAssureDx FDA completes current portion of substantive review in a timely manner Favorable Medicare reimbursement policy issued in July significantly increases GraftAssureDx surveillance testing opportunity Strong head-to-head data drive kitted customer interest NASHVILLE, TN., August 10, 2026 - Insight Molecular Diagnostics Inc., iMDx, (Nasdaq: IMDX), today published the following letter to shareholders in conjunction with its first quarter results: Fellow shareholders, We continue to be encouraged by progress toward our most important priority, which is to attain regulatory authorization of GraftAssureDx. In late July, the FDA completed the current phase of its substantive review of GraftAssureDx in a timely manner. The agency requested additional information from us, which is typical in a regulatory authorization process such as this. We view ourselves as being in the later stages of the review process, and after a thorough dialogue with the ag…

Open exhibit ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.